IN2014CN04734A - - Google Patents
Info
- Publication number
- IN2014CN04734A IN2014CN04734A IN4734CHN2014A IN2014CN04734A IN 2014CN04734 A IN2014CN04734 A IN 2014CN04734A IN 4734CHN2014 A IN4734CHN2014 A IN 4734CHN2014A IN 2014CN04734 A IN2014CN04734 A IN 2014CN04734A
- Authority
- IN
- India
- Prior art keywords
- cells
- vectors
- compositions
- biologically active
- provides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/85—Fusion polypeptide containing an RNA binding domain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
Abstract
Novel compounds compositions and methods for the delivery of biologically active RNA molecules to cells. Specifically the invention provides novel nucleic acid molecules polypeptides and RNA protein complexes useful for the delivery of biologically active RNAs to cells and polynucleotides encoding the same. The invention also provides vectors for expressing said polynucleotides. In addition the invention provides cells and compositions comprising the novel compounds and vectors which can be used as transfection reagents. The invention further provides methods for producing said compounds vectors cells and compositions. Additionally vectors and methods for delivering biologically active RNA molecules to cells and/or tissues are provided. The novel compounds vectors cells and compositions are useful for example in delivering biologically active RNA molecules to cells to modulate target gene expression in the diagnosis prevention amelioration and/or treatment of diseases discorders or conditions in a subject or organism.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161579815P | 2011-12-23 | 2011-12-23 | |
PCT/US2012/071576 WO2013096958A1 (en) | 2011-12-23 | 2012-12-24 | Compositions and methods for the delivery of biologically active rnas |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN04734A true IN2014CN04734A (en) | 2015-09-18 |
Family
ID=48654938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN4734CHN2014 IN2014CN04734A (en) | 2011-12-23 | 2012-12-24 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20130164845A1 (en) |
EP (1) | EP2794879A4 (en) |
JP (1) | JP2015507474A (en) |
KR (1) | KR20140123054A (en) |
CN (1) | CN104169419A (en) |
AU (1) | AU2012358181A1 (en) |
CA (1) | CA2860228A1 (en) |
HK (1) | HK1203548A1 (en) |
IN (1) | IN2014CN04734A (en) |
WO (1) | WO2013096958A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11639371B2 (en) * | 2016-02-17 | 2023-05-02 | The Chinese University Of Hong Kong | Peptidylic inhibitors of nucleolin (NCL) targeting CAG-repeat RNA toxicity and methods for reducing polyQ-mediated toxicity in polyQ diseases |
US11352625B2 (en) | 2017-01-12 | 2022-06-07 | Duke University | Compositions and methods for disrupting the molecular mechanisms associated with mitochondrial dysfunction and neurodegenerative disease |
AU2018291137A1 (en) * | 2017-06-28 | 2020-01-23 | University Of South Florida | Modified UBE3A gene for a gene therapy approach for Angelman syndrome |
MX2021009727A (en) * | 2019-02-15 | 2021-11-12 | Atreca Inc | Antibodies that bind tumor tissue, and their diagnostic and therapeutic uses. |
CN114395576B (en) * | 2020-08-31 | 2023-11-14 | 南京工业大学 | Method for improving protein expression efficiency in clostridium |
WO2022241480A1 (en) * | 2021-05-13 | 2022-11-17 | Technion Research & Development Foundation Limited | Methods and compositions for treatment of viral infection |
WO2023182870A1 (en) * | 2022-03-24 | 2023-09-28 | (주)셀레브레인 | Novel recombinant vector and use thereof |
EP4303305A1 (en) * | 2022-07-07 | 2024-01-10 | Kutzner, Christoph | Fusion polypeptides for cell penetration and cell targeting |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5585263A (en) * | 1994-05-20 | 1996-12-17 | University Of Alabama At Birmingham Research Foundation | Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV |
WO2004011624A2 (en) * | 2002-07-31 | 2004-02-05 | Nucleonics, Inc. | Double stranded rna structures and constructs, and methods for generating and using the same |
EP1658304A4 (en) * | 2002-09-28 | 2009-01-14 | Massachusetts Inst Technology | Influenza therapeutic |
WO2009002462A1 (en) * | 2007-06-22 | 2008-12-31 | The Board Of Trustees Of The Leland Stanford Junior University | Pre-mirna loop-modulated target regulation |
KR20110128345A (en) * | 2009-03-13 | 2011-11-29 | 에젠, 인코포레이티드 | Compositions and methods for the delivery of biologically active rnas |
JP6137834B2 (en) * | 2010-02-24 | 2017-05-31 | アローヘッド ファーマシューティカルズ インコーポレイテッド | Composition for targeted delivery of siRNA |
-
2012
- 2012-12-24 EP EP12859768.9A patent/EP2794879A4/en not_active Withdrawn
- 2012-12-24 WO PCT/US2012/071576 patent/WO2013096958A1/en active Application Filing
- 2012-12-24 CA CA2860228A patent/CA2860228A1/en not_active Abandoned
- 2012-12-24 AU AU2012358181A patent/AU2012358181A1/en not_active Abandoned
- 2012-12-24 US US13/726,337 patent/US20130164845A1/en not_active Abandoned
- 2012-12-24 JP JP2014549001A patent/JP2015507474A/en active Pending
- 2012-12-24 KR KR1020147020750A patent/KR20140123054A/en not_active Application Discontinuation
- 2012-12-24 IN IN4734CHN2014 patent/IN2014CN04734A/en unknown
- 2012-12-24 CN CN201280070535.5A patent/CN104169419A/en active Pending
-
2015
- 2015-04-22 HK HK15103893.5A patent/HK1203548A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN104169419A (en) | 2014-11-26 |
EP2794879A1 (en) | 2014-10-29 |
JP2015507474A (en) | 2015-03-12 |
KR20140123054A (en) | 2014-10-21 |
EP2794879A4 (en) | 2015-10-14 |
AU2012358181A1 (en) | 2014-07-10 |
US20130164845A1 (en) | 2013-06-27 |
WO2013096958A1 (en) | 2013-06-27 |
CA2860228A1 (en) | 2013-06-27 |
HK1203548A1 (en) | 2015-10-30 |
AU2012358181A8 (en) | 2015-06-18 |
WO2013096958A8 (en) | 2014-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN04734A (en) | ||
MX2020006065A (en) | Methods and products for nucleic acid production and delivery. | |
JOP20210207A1 (en) | Targeting Ligands | |
JOP20210231A1 (en) | Targeting Ligands For Therapeutic Compounds | |
WO2013158309A3 (en) | Non-disruptive gene targeting | |
MX2014007233A (en) | Modified nucleoside, nucleotide, and nucleic acid compositions. | |
WO2012075040A3 (en) | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES | |
MX2013006747A (en) | Peptide-based in vivo sirna delivery system. | |
MX2012002502A (en) | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids. | |
EP4241784A3 (en) | Artificial nucleic acid molecules for improved protein expression | |
MX357803B (en) | Artificial nucleic acid molecules. | |
MX358706B (en) | Artificial nucleic acid molecules comprising a 5'top utr. | |
CA2863964C (en) | Compartmentalized method of nucleic acid delivery and compositions and uses thereof | |
MX362981B (en) | Artificial nucleic acid molecules for improved protein or peptide expression. | |
MX346923B (en) | Genes and proteins for alkanoyl-coa synthesis. | |
WO2012019168A3 (en) | Engineered nucleic acids and methods of use thereof | |
MX342764B (en) | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types. | |
MX356625B (en) | Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell. | |
WO2012024396A3 (en) | Compositions and methods for delivering nucleic acid molecules and treating cancer | |
WO2011131360A3 (en) | Method of determining the metastatic potential of a tumor | |
MX2013007543A (en) | Pharmaceutical composition containing l-dna. | |
MX365599B (en) | C4s proteoglycan specific transporter molecules. | |
WO2021113851A3 (en) | Peptide docking vehicle for targeted nucleic acid delivery | |
MX2011007776A (en) | Compositions and methods for inhibiting expression of ptp1b genes. | |
WO2019060522A3 (en) | Thiomorpholino oligonucleotides for the treatment of muscular dystrophy |